HC Wainwright Reiterates "Buy" Rating for Precision BioSciences (NASDAQ:DTIL)

HC Wainwright restated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL - Free Report) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $60.00 target price on the stock. HC Wainwright also issued estimates for Precision BioSciences' Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.38) EPS and FY2025 earnings at ($2.77) EPS.

Precision BioSciences Price Performance

Shares of DTIL traded down $0.06 during mid-day trading on Wednesday, reaching $4.58. The company had a trading volume of 29,026 shares, compared to its average volume of 184,506. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company has a market capitalization of $50.78 million, a P/E ratio of 76.35 and a beta of 1.55. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $13.32. The company's 50-day moving average is $4.97 and its 200-day moving average is $5.32.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($1.78). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $5.00 million. Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. On average, equities analysts anticipate that Precision BioSciences will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Precision BioSciences

A number of large investors have recently bought and sold shares of DTIL. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Precision BioSciences by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company's stock valued at $59,000 after buying an additional 2,805 shares during the last quarter. Miller Financial Services LLC bought a new position in shares of Precision BioSciences in the first quarter worth about $48,000. Commonwealth Equity Services LLC bought a new position in shares of Precision BioSciences in the fourth quarter worth about $48,000. Samalin Investment Counsel LLC acquired a new position in shares of Precision BioSciences during the fourth quarter worth approximately $59,000. Finally, XTX Topco Ltd bought a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $67,000. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.